Raymond James & Associates Purchases 609 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Raymond James & Associates raised its position in United Therapeutics Co. (NASDAQ:UTHR) by 1.7% during the 3rd quarter, HoldingsChannel reports. The fund owned 35,751 shares of the biotechnology company’s stock after buying an additional 609 shares during the quarter. Raymond James & Associates’ holdings in United Therapeutics were worth $12,811,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Park Avenue Securities LLC boosted its stake in shares of United Therapeutics by 11.0% during the 1st quarter. Park Avenue Securities LLC now owns 1,562 shares of the biotechnology company’s stock worth $359,000 after buying an additional 155 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of United Therapeutics by 85.4% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 2,585 shares of the biotechnology company’s stock worth $594,000 after purchasing an additional 1,191 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its stake in shares of United Therapeutics by 14.4% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 3,291 shares of the biotechnology company’s stock worth $756,000 after purchasing an additional 413 shares in the last quarter. Diversified Trust Co boosted its holdings in shares of United Therapeutics by 286.6% in the 1st quarter. Diversified Trust Co now owns 5,045 shares of the biotechnology company’s stock valued at $1,159,000 after buying an additional 3,740 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of United Therapeutics by 1.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 184,934 shares of the biotechnology company’s stock valued at $42,483,000 after buying an additional 3,537 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

United Therapeutics Trading Down 0.4 %

Shares of United Therapeutics stock opened at $348.65 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35. The firm has a 50-day moving average of $354.00 and a 200-day moving average of $313.31. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $377.03. The stock has a market cap of $15.46 billion, a PE ratio of 16.48, a PEG ratio of 1.35 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The business had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. During the same period in the prior year, the firm earned $5.24 EPS. The business’s revenue for the quarter was up 19.8% on a year-over-year basis. As a group, sell-side analysts forecast that United Therapeutics Co. will post 24.72 EPS for the current year.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of recent analyst reports. Morgan Stanley cut shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price target for the company from $310.00 to $321.00 in a research note on Thursday, July 11th. Oppenheimer raised their target price on shares of United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a research note on Wednesday, August 28th. LADENBURG THALM/SH SH lowered United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. UBS Group raised their price objective on United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research report on Monday, July 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $400.00 target price on shares of United Therapeutics in a research note on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $361.33.

Insider Buying and Selling

In other news, CFO James Edgemond sold 7,785 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the completion of the sale, the chief financial officer now directly owns 2,615 shares in the company, valued at approximately $947,597.55. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CFO James Edgemond sold 7,785 shares of United Therapeutics stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $362.37, for a total value of $2,821,050.45. Following the transaction, the chief financial officer now directly owns 2,615 shares of the company’s stock, valued at $947,597.55. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Martine A. Rothblatt sold 269 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $348.41, for a total value of $93,722.29. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $45,293.30. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 102,812 shares of company stock valued at $35,251,926 over the last 90 days. 12.50% of the stock is owned by corporate insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.